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Abstract: The objective of this study was to assess current treatment patterns, blood glucose 
test strip usage, and treatment compliance in patients with type 2 diabetes mellitus (T2DM) in 
primary care centers in Spain, and to assess factors related to glycemic control. We conducted 
a retrospective chart review of patients with T2DM and measured treatment compliance using 
the Morisky-Green questionnaire. 294 patients were included in the study from a population of 
patients attending 30 primary care centers throughout Spain. Results showed that the majority 
of patients were treated with oral monotherapy (36%) and oral combination therapy (35%). 
Less than half of the patients had good glycemic control (HbA1c   6.5%). Half of the patients 
treated pharmacologically reported good compliance with treatment. Logistic regression analyses 
performed to identify factors associated with glycemic control showed that high body mass 
index (BMI) and poor compliance were the strongest predictors of poor HbA1c control (OR: 
2.198 and 1.789, respectively, p   0.05). In conclusion, in the course of managing diabetes, 
physicians and patients should attempt to improve compliance and lower BMI, which could 
lead to better glycemic control.
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Introduction
Diabetes mellitus is a highly prevalent, chronic disease which can signiﬁ  cantly impact 
morbidity and mortality. Type 2 diabetes mellitus (T2DM) is the most common form of 
diabetes and represents approximately 90% of all diagnosed cases of diabetes (Benito 
et al 2004). Although it is difﬁ  cult to calculate the prevalence of T2DM accurately 
because of variations in the rate of nondiagnosed cases ranging from 15% to 50% (Bayo 
et al 1996; Laing and Williams 1996; King et al 1998; Zimmet et al 2001), estimates 
of the prevalence of diabetes in Europe and North America range from 5% to 10% 
(Laing et al 1996). Prevalence in Spain is estimated to be about 6% (Bayo et al 1996; 
Tamayo-Marco et al 1997). The number of cases of diabetes in Spain is therefore 
high and is expected to continue rising. According to the World Health Organization 
(WHO), in the year 2000, there were approximately 2.7 million cases of diabetes in 
Spain and the number was expected to increase to over 3.7 million by 2030 (WHO 
2007). Diabetes is associated with chronic microvascular and macrovascular complica-
tions, such as a blindness and cardiovascular disease, and is one of the leading causes 
of death worldwide and in Spain (Benach et al 2001; Roglic et al 2005). In 2004, the 
standardized mortality rate was estimated to be approximately 14 per 100,000 in Spain 
(WHO Regional Ofﬁ  ce for Europe 2007).
In addition to physician-prescribed treatment, patient behavior is also critical in 
determining the success of the treatment. For patients with type 2 diabetes, attention 
to diet, exercise, blood glucose monitoring, and medication are necessary to achieve Patient Preference and Adherence 2008:2 88
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good glycemic control (Cramer 2004). Poor compliance may 
also lead to poor outcomes with pharmacological treatment, 
though compliance with diabetes treatment has not been 
widely studied. Self-monitoring of blood glucose could also 
play a role in improving treatment outcomes. This is espe-
cially true with insulin treatment because patients can adjust 
their dose depending on the outcome of their blood glucose 
test results. The American Diabetes Association (ADA) 
recommends self-monitoring of blood glucose (SMBG) as 
an important component of the care of all patients treated 
with insulin. However, the role and optimum frequency of 
such monitoring in patients with T2DM is still under debate 
(Farmer et al 2007), particularly in the case of patients 
receiving noninsulin treatment. Excessive use of SMBG can 
also lead to signiﬁ  cant economic expense and psychological 
impact (Gallichan 1997). To inform this debate, it would be 
useful to know the current level of test strip usage for patients 
with diabetes in Spain.
Because little information was available on how patients 
with T2DM are treated in the primary care setting in Spain, 
this study was designed to identify current treatment pat-
terns, to assess patients’ compliance with their treatment 
plans, and to estimate the use of blood glucose test strips. 
A further objective of the study was to determine which 
sociodemographic and clinical variables were most closely 
associated with the likelihood of achieving target levels of 
glycemic control and thus with reducing the risk of morbidity 
and mortality.
Methods
This was a retrospective medical chart review of patients with 
T2DM. Data collected included patient background informa-
tion and a patient self-assessment of treatment compliance. 
A total of 30 primary care physicians took part in the study 
from July 2005 to September 2006 and were selected from 16 
autonomous regions based on the geographical distribution 
of the population of Spain (Table 1).
To be included in the study, patients had to be over 20 
years of age and to have had T2DM (diagnosed using ADA 
criteria) (ADA 2005) for at least one year. Inclusion was also 
dependent on the availability in the healthcare center of a 
clinical record containing minimum basic information (ie, age, 
gender, educational level, duration of diabetes/age at diagno-
sis,  1 HbA1c record within the last 12 months, a list of any 
prescribed glucose-lowering medications that were taken dur-
ing the three months prior to the HbA1c test, a body mass index 
(BMI) value within the six months prior to the HbA1c test, 
and documentation concerning the current glucose-lowering 
treatment regimen). Each physician included up to 10 patients 
in the study. Potential candidates for inclusion were asked to 
participate during one of their scheduled visits. Patients agree-
ing to participate were requested to sign an informed consent 
form and were then given the study materials including the 
Morisky-Green questionnaire on treatment compliance. 
Sociodemographic and clinical variables relating to diabetes 
history, treatment patterns (duration and type of treatment), 
and current use of test strips (times per week) were collected 
by the physician from patients’ clinical records. Patients’ waist 
circumference was measured during this ofﬁ  ce visit. The study 
was approved by the ethics committee of the Fundació Jordi 
Gol i Gurina, Barcelona, Spain.
Table 1 Distribution of sample by geographical zones 
and autonomous regions
Geographical
areas
Autonomous
regions
n (%)
East (34.6%)* Aragon 10 (3.4%)
Balearic Islands 8 (2.7%)
Catalonia 51 (17.3%)
Murcia 10 (3.4%)
Valencia 28 (9.5%)
Total 107 (36.4%)
North (16.8%)* Asturias 13 (4.4%)
Cantabria 10 (3.4%)
Galicia 10 (3.4%)
La Rioja 10 (3.4%)
Navarre 6 (2%)
Total 49 (16.7%)
South (25.1%)* Andalusia 47 (16%)
Canary Islands 12 (4.1%)
Extremadura 13 (4.4%)
Total 72 (24.5%)
Center (23.5%)* Castilla-La Mancha 13 (4.4%)
Castilla y León 14 (4.8%)
Madrid 39 (13.3%)
Total 66 (22.4%)
Notes: *Percentage of the total Spanish population (INE 2006).Patient Preference and Adherence 2008:2 89
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Treatment compliance
Treatment compliance was assessed using the Spanish ver-
sion of the self-administered Morisky-Green questionnaire. 
The questionnaire has been shown to have good internal 
reliability (Morisky et al 1986) and consists of the following 
four items:
1.  Do you ever forget to take your medicine?
2.  Are you careless at times about taking your medica-
tion?
3.  When you feel better, do you sometimes stop taking your 
medicine?
4.  Sometimes if you feel worse when you take the medicine, 
do you stop taking it?
Response options are dichotomous (yes = 1, no  = 0). The 
total score ranges from 0 to 4. Treatment compliance was 
categorized as high (score = 0), moderate (score between 1 
and 2), and low (score  3) based on the overall Morisky-
Green score. This questionnaire was administered only to 
patients receiving pharmacological treatment. Treatment 
compliance was analyzed descriptively and comparatively 
based on treatment type.
Analysis
Data analysis was performed using SAS 8.02 software 
(SAS Inc., Cary, NC, USA). A signiﬁ  cance level of less 
than 0.05 was used as a criterion for statistical signiﬁ  cance 
in all statistical comparisons. Prior to performing statistical 
analyses, data completeness and data quality were assessed. 
In general, analysis of variance (ANOVA) was used to 
analyze continuous variables and the χ2 test was used for 
categorical variables. Other statistical techniques were used 
as required.
A descriptive analysis of sociodemographic character-
istics and T2DM history was performed. Current treatment 
patterns and the length of time the patient had been receiv-
ing pharmacological treatment were assessed. For patients 
on insulin treatment, the current number of insulin units per 
week and the type of insulin (brand name) were collected at 
1, 6, 12, and 18 months after initiation of insulin treatment. 
In addition, the proportion of patients using glucose test 
strips for SMBG and the number of times per week they 
used them were analyzed for the sample as a whole and by 
treatment type. Patients were categorized by BMI as follows: 
overweight (25   BMI   30), obese (30   BMI   35) or 
severely obese (BMI   35).
A logistic regression was conducted to analyze factors 
associated with the level of compliance. The dependent vari-
able was categorized as high, moderate or low compliance. 
The independent variables used in the model were: treatment 
type (treatment with oral antidiabetic medications [OAMs], 
and insulin treatment with or without OAM[s]), HbA1c 
value, sociodemographic variables, and complications of 
diabetes mellitus (no complications, only microvascular 
complications, only macrovascular complications, and both 
microvascular and macrovascular complications).
A second logistic regression was conducted to analyze 
factors associated with the level of HbA1c control. The 
dependent variable was deﬁ  ned as a dichotomous variable, 
which categorized an HbA1c of less than or equal to 6.5% as 
good glycemic control and an HbA1c of greater than 6.5% as 
poor glycemic control (IDF 2005). The independent variables 
introduced were: patient education level (completed at least 
primary education and less than primary education), number 
of years since T2DM diagnosis, patient treatment (no phar-
macological treatment, treatment with OAM[s], and insulin 
treatment with or without OAM[s]), BMI (nonobese versus 
obese/severely obese), vascular complications of diabetes 
mellitus (no complications, only microvascular complications, 
only macrovascular complications, and both microvascular 
and macrovascular complications), and treatment compliance 
(high compliance versus low/moderate compliance).
Results
A total of 339 patients with T2DM visited their physicians 
during the study period. Of these, 294 (86.7%) were selected 
to take part in the study. Of the 45 patients that did not partici-
pate, the main reasons for nonparticipation were: no available 
data (35.7%), did not meet inclusion criteria (30.8%), with-
held consent to take part in the study (11.5%), and exclusion 
for other reasons (22%). Because the study consisted of only 
one visit, there were no withdrawals during the study.
Patient characteristics
Patient sociodemographic data are shown in Table 2. Equal 
numbers of men and women were included. Mean age was 
67.5 (standard deviation [SD] = 10.2) years and more than 
58% of patients were over 65 years of age. Most patients 
reported having completed at least primary education. 
Approximately 95% of the study population was European. 
Approximately 12% of patients were smokers (about half 
of these individuals smoked between 10 and 20 cigarettes 
per day) and 20% of patients reported consuming alcohol. 
Almost half of the patients had a family history of diabetes 
and the average time since diagnosis was 9.9 years (SD = 8.7). 
Table 3 shows patients’ clinical characteristics. Glycemic 
control was considered to be good (HbA1c less than or equal to Patient Preference and Adherence 2008:2 90
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6.5%) in fewer than half of the patients. Almost half of patients 
in this study (47.4%) had microvascular complications, mac-
rovascular complications, or both micro- and macrovascular 
complications. More speciﬁ  cally, cardiovascular disease was 
present in 38.1% of the patients, renal complications in 28.9%, 
retinopathy complications in 17.7%, neuropathy in 12.2%, and 
foot ulcer complications in 4.1%. In terms of body weight, only 
16.1% of patients had a BMI that was considered normal or 
underweight (BMI less than 25). More than 45% were over-
weight (25   BMI  30), and 38% were obese (30   BMI  35) 
or severely obese (BMI   35). The mean BMI was 28.9 kg/m2 
(SD = 4.5), and the mean waist circumference was 99.2 cm 
(SD = 16.2). With regard to duration of T2DM, 34.5% had 
had T2DM for  6 years; 43% between 6 and 14 years, and 
22.5%  15 years. As expected, the mean HbA1c was higher for 
patients with diabetes complications. HbA1c was also higher for 
patients with a higher BMI and was generally higher in patients 
who had been diabetic for longer.
Treatment patterns
Almost all (93.9%) study participants were receiving 
some form of pharmacological treatment for their diabetes 
(Table 3). On average, patients had been receiving treatment 
for 8.2 years (SD = 7.5). The most common treatments were 
oral monotherapy (35.7%) and therapy with more than 
one OAM (34.7%). With regard to the type of treatment, 
43.8% of the patients who received oral monotherapy used 
metformin and 40% used sulfonylureas. Of those receiv-
ing oral combination therapy, 60.8% took a combination 
of metformin and sulfonylureas. A total of 23.5% of the 
Table 2 Description of sociodemographic characteristics 
of T2DM patients included in this study
Sex (n, %)
Male 147 (50%)
Female 147 (50%)
Age (years)
Mean (SD) 67.5 (10.2)
Range 24–91
 65 years old 123 (41.8%)
 65 years old 171 (58.2%)
Level of education (n, %)
Below primary studies 99 (33.9%)
Completion of primary studies 136 (46.6%)
Completion of secondary studies 39 (13.4%)
At least completion of university studies 18 (6.1%)
Ethnicity (n, %)
European 280 (95.2%)
Other 14 (4.8%)
Smoking habit (n, %) 35 (11.9%)
Alcohol consumption (n, %) 59 (20.6%)
Family history of diabetes 136 (46.4%)
Time since T2DM diagnosis (years)
Mean (SD) 9.9 (8.7)
Abbreviations: SD, standard deviation; T2DM, type 2 diabetes mellitus.
Table 3 Clinical characteristics of T2DM patients and mean 
HbA1c per group
Clinical characteristic n,  % Mean (SD) 
HbA1c
P value*
Level of glycemic control
HbA1c  6.5 123 (41.8%)
HbA1c  6.5 and  7 62 (21.1%)
HbA1c  7 and  8 64 (21.8%)
HbA1c  8 45 (15.3%)
Diabetes complications
No complications 150 (52.6%) 6.69 (1.48) (P   0.001)
Microvascular complications 60 (21.1%) 6.92 (1.17)
Macrovascular complications 33 (11.6%) 6.61 (1.21)
Microvascular and macrovas-
cular complications
42 (14.7%) 7.68 (1.75)
BMI
Mean (SD) 28.9 (4.5)
Normal or underweight 
(BMI   25)
45 (16.1%) 6.58 (1.51) (P   0.05)
Overweight (25   
BMI   30)
128 (45.9%) 6.65 (1.30)
Obese (30   BMI   35) 75 (26.9%) 7.16 (1.67)
Severely obese (BMI   35) 31 (11.1%) 7.45 (1.34)
Duration of T2DM
Mean (SD) 9.9 years (8.7)
 2 years 48 (16.4%) 6.28 (1.38) (P   0.001)
3–5 years 53 (18.1%) 6.70 (1.48)
6–9 years 81 (27.6%) 6.88 (1.46)
10–14 years 45 (15.4%) 7.40 (1.83)
 15 years 66 (22.5%) 7.08 (1.09)
Treatment
No pharmacological treat-
ment
18 (6.1%) 6.04 (0.69) (P   0.05)
Oral monotherapy 105 (35.7%) 6.52 (1.10)
Oral combination therapy 102 (34.7%) 7.05 (1.65)
Insulin monotherapy 24 (8.2%) 7.19 (1.31)
Insulin combination therapy 8 (2.7%) 8.00 (1.27)
Insulin and oral treatment 37 (12.6%) 7.72 (1.97)
Notes: *p values indicate level of signiﬁ  cance in differences of HbA1c values among 
categories in ANOVA test.
Abbreviations: ANOVA, analysis of variance; BMI, body mass index; SD, standard 
deviation; T2DM, type 2 diabetes mellitus.Patient Preference and Adherence 2008:2 91
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study participants were on insulin therapy: 8.2% of the total 
sample used only one insulin, 2.7% used a combination of 
more than one type of insulin, and 12.6% of patients were 
treated with a combination of insulin and OAM(s). The most 
commonly prescribed type of insulin among these patients 
was intermediate-acting (49.3%), followed by the combina-
tion of intermediate-acting and fast-acting (30.4%) insulins. 
The least prescribed type of insulin was fast-acting insulin 
alone (14.5%). The mean number of insulin units per week 
was 262.37 (SD = 124. 17), or about 37 insulin units daily. 
The mean HbA1c generally increased in patients on more 
intensive therapy, which is likely due to the longer duration 
of disease for patients taking insulin. The mean HbA1c was 
lowest in patients on no pharmacological treatment (mean 
= 6.04, SD = 0.69) and highest in patients taking more than 
one type of insulin therapy (mean = 8.00, SD = 1.27).
Analysis of treatment patterns according to time since 
diagnosis showed that oral monotherapy was the most com-
mon treatment in patients with  2 years since diagnosis 
(Figure 1). For all other patients (ie, patients with more than 
2 years since diagnosis), the most common treatment was 
an oral combination therapy. Nevertheless, insulin treatment 
became more frequent the longer the duration of diabetes. 
In patients with a time since diagnosis over 15 years, 55% 
were treated with insulin, either alone or in combination 
with an OAM(s).
A total of 66% of patients used test strips to monitor their 
blood glucose levels (Table 4). There were statistically sig-
niﬁ  cant differences among groups regarding test-strips usage 
according to their T2DM treatment type (p   0.05). Among 
patients treated with insulin,  90% used test strips, whereas 
among patients with no treatment or who were only taking 
oral treatment, the corresponding percentages were 33.3% 
and 59.4%, respectively. The number of test strips used per 
week was higher in patients taking insulin (ranging from 6.3 
to 7.7) than in those with no treatment or only oral treatment 
(5.2 and 4.4, respectively). The number of strips used was 
numerically higher in the group who were not receiving 
pharmacological treatment compared with the group on oral 
therapy but the difference was not statistically signiﬁ  cant.
Table 5 reports patient compliance by treatment type. 
Using the self-administered Morisky-Green questionnaire, 
50 % of patients taking a pharmacological treatment reported 
high compliance with treatment. The highest proportion of 
patients reporting good compliance (67%) was found in 
the group treated with insulin monotherapy, and the low-
est proportion (39%) was in patients treated with insulin in 
combination with OAM(s). Treatment type and HbA1c level 
were the only signiﬁ  cant factors related to compliance in 
the multivariate logistic regression analysis that examined 
factors related to levels of compliance after controlling for 
socio-demographic variables and complications. More spe-
ciﬁ  cally, the results showed that the probability of having a 
high level of compliance is signiﬁ  cantly higher in patients 
receiving only insulin (OR: 2.7) than in patients on OAM(s). 
Moreover, the likelihood of better compliance increases with 
lower HbA1c values (OR of 1.3 for improved compliance 
given a one percentage point reduction in HbA1c values).
Table 6 shows the outcomes of the logistic regression to 
examine factors associated with poor glycemic control. Level 
of education, T2DM duration, treatment type, and presence 
and type of complications were not individually signiﬁ  cant. 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
<=2 yrs 3 to 5 yrs 6 to 9 yrs 10 to 14 yrs 15+ yrs
Insulin and oral
treatment
Insulin combination
therapy
Insulin monotherapy
Oral combination
therapy
Oral monotherapy
No pharmacological
treatment
Figure 1 Distribution of current treatment patterns of T2DM patients according to number of years since T2DM diagnosis.
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The only signiﬁ  cant variables (p   0.05) were obesity and 
treatment compliance (ORs of 2.193 and 1.789, respectively, 
for patients with a BMI greater than 30 and for patients with 
low to moderate compliance).
Discussion
This study provides a general overview of the management 
of T2DM in Spain from both a physician and a patient per-
spective. Physicians who took part in the study were selected 
so as to provide a representative sample based on popula-
tion distribution in Spain. Typical of studies in T2DM, the 
population included in the study had a high mean age. The 
population was equally distributed in terms of sex. A rela-
tively low percentage of patients in this study had completed 
secondary or university studies (about 20%); however, educa-
tion level did not explain glycemic control in the multivariate 
analysis. With regard to lifestyle, the percentage of smokers 
and drinkers is similar to that of other studies (Benito et al 
2004; Arroyo et al 2005), but less than that reported for the 
Spanish population as a whole (Clemente et al 1999). This 
low percentage could be explained by the fact that it relied 
on patient self-reports. Over 80% of patients had a BMI of 
 25 kg/m2, which is similar to other studies indicating that up 
to 90% of the T2DM population is overweight (Tremble and 
Donaldson 1999). The percentage of patients with a family 
history of T2DM and the mean duration of the disease (about 
10 years) were also comparable to ﬁ  gures in other Spanish 
studies (González-Clemente 1997; Zorrilla Torras et al 1997; 
Clua Espuny et al 1999; Arroyo et al 2005).
The ADA (ADA 2006) recommends that HbA1c in dia-
betes patients should be under 7% as these levels of HbA1c 
are associated with a lower risk of long-term microvascular 
complications. Nevertheless, a 7% threshold does not com-
pletely rule out the risk of complications and other medical 
societies have proposed a lower level of 6.5% (BCS et al 
2005; IDF 2005). Of the patients in this study, 42% had an 
HbA1c less than or equal to 6.5%, and 63% had an HbA1c of 
less than or equal to 7%. These values are similar to those 
from other studies carried out in Spain: Mata Cases and 
colleagues (2003) reported 62% of patients with an HbA1c 
 7.5% and Sender Palacios and colleagues (2002) reported 
a similar percentage (66%). Different estimates of the pro-
portion of individuals with good glycemic control have been 
obtained in other settings. For example, in a study carried out 
in the United States, Spann and colleagues (2006) reported 
that only 40% of patients had an HbA1c level less than or 
equal to 7%. These data were similar to those observed in 
the Third National Health and Nutrition Examination Survey 
Table 4 Proportion of use of test strips and test strip usage per week of type of pharmacological treatment
No treatment Oral treatment Insulin Insulin and oral treatment Total
Use of test strips n (%)
Yes 6 (33.3%)A,B,C 123 (59.4%)A,B,C 31 (96.9%)B 34 (91.9%)C 194 (66%)
No 12 (66.7%) 84 (40.6%) 1 (3.1%) 3 (8.1%) 100 (34%)
Test strips per week
Mean (SD) 5.2 (2.9) 4.4 (3.8) 7.7 (6.4) 6.3 (5.8) 5.3 (4.8)
Range 1–7 1–18 1–21 1–21 1–21
Notes: In each row, statistically signiﬁ  cant differences (p   0.05) were obtained between values with the same letter ( A, B, or C). A compares “oral treatment” with “no 
treatment”; B compares “no treatment” with “oral treatment” and with “insulin treatment,”; and C compares “no treatment” with “oral treatment” and with “insulin and 
oral treatment.”
Table 5 Percentage of patients with reporting various levels of treatment compliance by type of pharmacological treatment
Compliance (%) No pharmacolog-
ical treatment
All treatments Oral treatment Insulin treat-
ment
Oral monotherapy Oral treatment 
combination
Insulin 
monotherapy
Insulin 
combination
Insulin 
and oral 
treatment
High compliance n.a. 50 49 50 67 57 39
Moderate compliance n.a. 41 41 42 29 29 47
Low compliance n.a. 9 10 8 4 14 14
Abbreviation: n.a., not applicable.Patient Preference and Adherence 2008:2 93
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(Harris 2000), which was conducted between 1991 and 1994 
and which reported 42.3% of patients with an HbA1c under 
7%. A recent retrospective study (Grant et al 2005) of gen-
eral practice and endocrine specialists in the United States 
demonstrated even poorer levels of control, with only 34% 
of patients achieving glycemic control targets. Although this 
may indicate that glycemic control is better in Spain, it may 
also be due to different methodological characteristics. For 
example, in our study, only patients treated by general prac-
titioners were included. By not including patients treated by 
diabetes specialists we may have biased our sample towards 
patients with better glycemic control.
Regardless of the comparisons, the HbA1c values are 
clearly suboptimal. One possible reason for this is that 
patients are noncompliant with their prescribed treatment 
regimen. Another possibility is that in real clinical prac-
tice, physicians prescribe insufﬁ  cient hypoglycemic drugs. 
Although we found that patients receiving more than one 
hypoglycemic drug and/or insulin had worse glucose control 
than patients on none or only one oral hypoglycemic drug, 
this is probably because the most severe patients are usually 
treated with a greater number of drugs. In similar studies of 
primary care patients, a signiﬁ  cant correlation was found to 
exist between levels of HbA1c and diabetes duration (Fernán-
dez Herraez et al 1999). This illustrates how difﬁ  cult it is 
for physicians and patients to manage T2DM and to achieve 
control objectives when the disease progresses and multiple 
medications are subsequently needed (UKPDS 1998).
It is worth noting that, despite a mean duration with 
the disease of almost 10 years and, therefore, progressive 
beta-cell failure, only 34.7% of patients were receiving oral 
combination therapy and 23.5% received insulin alone or in 
combination. The relatively low use of drug combinations or 
insulin in clinical practice is surprising given the well-known 
ﬁ  ndings of landmark studies, which have demonstrated that a 
greater use of these therapies lead to better HbA1c control. For 
example, the United Kingdom Prospective Diabetes Study 
(UKPDS) showed that only 24% of patients treated with 
sulfonylureas in monotherapy and 13% of those treated with 
metformin maintained levels of HbA1c lower than 7% after 9 
years of treatment. In more than 50% of the cases, combined 
therapy was needed to achieve better HbA1c control (Turner 
et al 1999). Nevertheless, the prescription of hypoglycemic 
drugs in actual clinical practice appears to be suboptimal 
(Mata Cases et al 2003; Spann et al 2006).
Although some oral hypoglycemic drugs can produce 
hypoglycemia, it is a more frequent problem in patients treated 
with insulin. Therefore, blood glucose monitoring is suggested 
to help optimize dosing and to avoid hypoglycemia. Consis-
tent with these guidelines, the results of this study suggest 
that patients taking insulin regularly test their blood glucose 
levels. The generally accepted diabetes guidelines in Spain do 
not recommend self-monitoring in patients who are treated 
with diet only (García Soidán et al 2005). The same is true of 
the ADA guidelines, which also do not establish an optimum 
frequency or regularity of self-monitoring in patients treated 
with OAMs (ADA 2006). Our study showed a high use of test 
strips in patients treated only with diet or OAMs. Other studies 
conducted in Spain also show test strip usage which are above 
the recommended levels (Olveira et al 1998; Clua Espuny et al 
1999). The high use of test strips produces signiﬁ  cant costs 
to the Spanish health system yet there is still some debate as 
to whether these higher monitoring costs lead to improved 
outcomes (Oliva et al 2004; Guerci et al 2003; Franciosi et al 
2005; Martín et al 2006). Some critics even suggest that such 
monitoring could worsen a patient’s metabolic control and 
cause greater psychological problems (Oliva et al 2004). Given 
the controversy regarding the effectiveness of SMBG in patients 
treated with diet or with an OAM, it is surprising that patients 
on these treatments make such frequent use of test strips.
Table 6 Logistic regression of HbA1c control
Parameter Pr   ChiSq OR CI OR 95%
Intercept 0.3856
At least completed pri-
mary studies (vs below than 
primary studies)
0.2692 0.714 0.392–1.298
Number of years since 
T2DM diagnosis
0.1075 1.038 0.992–1.085
Insulin treatment (vs no 
drug treatment)
0.4418 2.273 0.103–5.076
Oral treatment (vs no 
drug treatment)
0.7447 1.382 0.759–3.564
Obese/severely obese 
(vs nonobese)
0.0092 2.193 1.214–3.959
Macrovascular complications 
(vs no complications)
0.8684 0.929 0.389–2.219
Microvascular complications 
(vs no complications)
0.1485 1.729 0.823–3.633
Micro and macrovascular 
(vs no complications)
0.1678 1.932 0.758–4.925
Low/moderate compliance 
(vs high compliance)
0.0402 1.789 1.026–3.119
Notes: Dependent variable HbA1c scored as 0 for values  6.5% and 1 for values 
 6.5%.
Abbreviations: CI, conﬁ  dence interval; OR, odds ratio; T2DM, type 2 diabetes 
mellitus.Patient Preference and Adherence 2008:2 94
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According to the results of this study, fewer than 50% of 
patients on pharmacological treatment reported high compli-
ance. The proportion of good compliers was higher in patients 
treated in insulin than in those treated with OAMs and much 
lower in those treated with a combination of insulin and OAMs. 
Although it might be expected that compliance would be lower 
for injectable treatments, our results suggest that compliance is 
related more to the severity of diabetes than to the type of drug 
administration. Insulin treatment may also have a psychologi-
cal effect on the patient in the sense that initiating treatment 
with insulin forces the patient to think seriously about the dis-
ease and possibly makes the patient more conscientious about 
taking his or her medication. Our results are consistent with a 
systematic review of compliance to diabetes treatment, which 
concluded that many diabetic patients complied poorly with 
treatment that included both OAMs and insulin and indicated 
that, as with other chronic diseases, treatment compliance was 
not related to the complexity of the treatment regimen, the 
severity of the disease, or the possible consequences of the 
forgotten doses (Cramer 2004).
Some of the most interesting contributions of the cur-
rent study may be the conclusions derived from the logistic 
regression analysis conducted to determine the factors associ-
ated with glycemic control. The results show that treatment 
compliance and BMI are the best predictors for not achieving 
optimal glycemic control. In our model, patient education 
level, treatment type, disease progression, and the presence and 
type of complications were not signiﬁ  cantly associated with 
poor HbA1c control. While other studies have also examined 
predictors of glycemic control, our study includes an important 
variable that is often missing in these types of analyses, namely, 
compliance (Sender Palacios et al 2002; Díaz Grávalos et al 
2006; Spann et al 2006). The fact that the two most important 
variables – BMI and compliance – are largely dependent on the 
patient’s behavior, demonstrates the importance of the patient’s 
role in achieving target clinical outcomes. Clinicians should 
continue to help their patients to understand the importance of 
weight management and treatment compliance and how they 
are associated with clinical outcomes, such as HbA1c control.
This study provides a comprehensive examination of 
actual clinical practice for patients with type 2 diabetes in 
Spain; however, the study had several limitations. First, the 
recruitment of patients from among those consulting their 
physician within a three-month period inﬂ  uenced selection. 
Although all patients with diabetes, including those with dif-
ferent treatment patterns and at different stages of the disease, 
should consult their physicians, the three-month enrolment 
period could have led to the recruitment of patients who 
consult more regularly with their physicians. The direction 
of this bias is unknown as patients in good health may be 
in good health because they see their physicians more often 
and our sample would therefore tend to include patients 
with better outcomes. On the other hand, patients with poor 
health may visit their physicians more often and in that case 
our sample would be biased towards patients with a poorer 
health status. Another source of potential bias for this study 
was recruiting only patients who were treated by a general 
practitioner. As more patients with poor glycemic control 
are likely treated by diabetes specialists, the results from 
our study are not likely to be representative of the overall 
management and outcomes of patients with type 2 diabetes 
in Spain. Finally, an indirect method which relies on patient 
self-report (ie, the Morisky-Green questionnaire) was used 
to measure treatment compliance. This might be expected 
to produce inﬂ  ated compliance scores; however, the propor-
tion of patients reporting good compliance in our study was 
actually lower than that found in other recent studies on 
compliance (Grant et al 2003; Mino-Leon et al 2005).
In conclusion, we observed that fewer than half of all 
patients with T2DM being treated by primary care physicians 
in Spain have a good level of glycemic control. The worst 
levels of glycemic control were observed in patients on insulin 
therapy. Although this may be due to the fact that these patients 
have a more advanced form of diabetes, the results may also 
indicate that insulin treatment should be better managed in this 
population. We also found that fewer than half of the patients 
included who were using pharmacological treatment reported 
having high compliance with their treatment. Patients on insu-
lin monotherapy and insulin combination therapy reported the 
highest levels of compliance. This is perhaps surprising con-
sidering that injectable administration is typically considered 
more bothersome than oral administration. However, patients 
on insulin may recognize the severity of the disease more than 
patients on OAM(s). Patients also report a high frequency 
of blood glucose monitoring, including frequent use of test 
strips among patients who were not using insulin. This is not 
consistent with treatment guidelines in Spain and it is not 
clear whether or not such monitoring is warranted. Healthcare 
providers may need to consider health education programs 
to help patients determine how frequently they should self-
monitor their blood glucose. Finally, given the results of the 
analysis of the factors most strongly associated with glycemic 
control, special attention should be paid to treatment compli-
ance and BMI. In the course of managing diabetes, physicians 
and patients should attempt to improve compliance and lower 
BMI, which could lead to better glycemic control.Patient Preference and Adherence 2008:2 95
Type 2 diabetes management in spain
Disclosure
Funding for this study was provided by Eli Lilly and 
Company.
References
[ADA] American Diabetes Association. 2005. Diagnosis and classiﬁ  cation 
of diabetes mellitus. Diabetes Care, 28:S37–S42.
[ADA] American Diabetes Association. 2006 Standards of medical care in 
diabetes. Diabetes Care, 29(Suppl 1):S4–42.
Arroyo J, Badía X, de la Calle H, et al. 2005. Tratamiento de los pacien-
tes con disbetes mellitus tipo 2 en españa. Medicina Clínica (Barc), 
125:166–72.
Bayo J, Latorre PM, García F, et al. 1996. Factores de riesgo asociados a 
la prevalencia de diabetes mellitus no insulinodependiente en Lejona 
(Vizaya). Medicina Clínica (Barc), 107:572–7.
Benach J, Yasui Y, Borrell C, et al. 2001. Material deprivation and leading 
causes of death by gender: evidence from a nationwide small area study. 
J Epidemiol Community Health, 55:239–45.
Benito LP, Garcia MR, Puig DM, et al. 2004. Pathological characteristics of 
patients with diabetes mellitus type 2 in Spanish primary care. Revista 
Clínica Española, 204:18–24.
[BCS] British Cardiac Society, British Hypertension Society, Diabe-
tes UK, et al. 2005. JBS2: Joint British Societies’ guidelines on 
prevention of cardiovascular disease in clinical practice. Heart, 
91(Suppl. 5):1–52.
Clemente ML, Alonso JA, Córdoba R, et al. 1999. Descripción de las guías 
disponibles en España para el abordaje del tabaquismo en Atención 
Primaria. Atención Primaria, 24:101–8.
Clua Espuny JL, Puig Junoy J, Ciuranan Roca E, et al. 1999. Self-monitoring 
of blood glucose: evaluation of its prescription and results in type-2 
diabetes. Atención Primaria, 24:316–25.
Cramer JA. 2004. A systematic review of adherence with medications for 
diabetes. Diabetes Care, 27:1218–24.
Díaz Grávalos GK, Palmeiro Fernández G, Casado Górriz I, et al. 2006. 
Cumplimiento de los objetivos de control metabólico en diabetes 
mellitus en el medio rural de Ourense. Revista Española de Salud 
Pública, 80:67–75.
Farmer A, Wade A, Goyder E, et al. 2007. Impact of self monitoring of 
blood glucose in the management of patients with non-insulin treated 
diabetes: open parallel group randomised trial. BMJ, 335:132.
Fernández Herraez E, Ferré Larrosa F, Jiménez Alfonso L, et al. 1999. 
Valoración de los factores relacionados con el control de la glucemia 
en la diabetes mellitus tipo 2. Atención Primaria, 24:39–43.
Franciosi M, Pellegrini F, De Berardis G, et al. 2005. Self-monitoring of blood 
glucose in non-insulin treated diabetic patients: a longitudinal evaluation 
of its impact on metabolic control. Diabetic Med, 22:900–6.
Gallichan M. 1997. Self monitoring of glucose by people with diabetes: 
evidence based practice. BMJ, 314:964–7.
García Soidán FJ, Novo Rodríguez JM, Vázquez Troitiño F, et al. 2005. Dia-
betes Mellitus tipo 2 [online]. Guías Clínicas, 5(15). Accessed on March 
3, 2007. URL: http://www.ﬁ  sterra.com/guias2/diabetes_mellitus.asp.
González-Clemente JM. 1997. Non-insulin dependent diabetes mellitus: care 
in an area of Barcelona. Medicina Clínica (Barc), 108:91–7.
Grant RW, Buse JB, Meigs JB. 2005. Quality of diabetes care in US aca-
demic medical centers: low rates of medical regimen change. Diabetes 
Care, 28:337–442.
Grant RW, Devita NG, Singer DE, et al. 2003. Polypharmacy and medi-
cation adherence in patients with type 2 diabetes. Diabetes Care, 
26:1408–12.
Guerci B, Drouin P, Grange V, et al. 2003. Self-monitoring of blood glu-
cose signiﬁ  cantly improves metabolic control in patients with type 2 
diabetes mellitus: the Auto-Surveillance Intervention Active Study. 
Diabet Metabol, 29:587–94.
Harris MI. 2000. Health care and health status and outcomes for patients 
with type 2 diabetes. Diabetes Care, 23:754–8.
[IDF] International Diabetes Federation. 2005. Global guideline for type 
2 diabetes [online]. Accessed March 3, 2007. URL: http://www.idf.
org/webdata/docs/IDF%20GGT2D.pdf.
[INE] Instituto Nacional de Estadistica [National Institute of Statistics]. 
2006. Population referring to January 1, 2005 by autonomous com-
munities and sex. Demographics and Population. INEbase [online]. 
Madrid: National Institute of Statistics. Accessed on December 14, 
2006. URL: http://www.ine.es.
King H, Aubert RE, Herman WH. 1998. Global burden of diabetes 
1995–2025: prevalence, numerical estimates, and projections. Diabetes 
Care, 21:1414–31.
Laing W, Williams R. 1996. Diabetes, a model for health care management, 
Ofﬁ  ce of Health Economics, London, 1989 (Paper 92). Cited by: Marks 
L. Counting the cost: the real impact of non-insulin-dependent diabetes. A 
King’s Fund report commissioned by the British Diabetic Association.
Martín S, Schneider B, Heinemann L, et al. 2006. Self-monitoring of blood 
glucose in type 2 diabetes and long-term outcome: an epidemiological 
cohort study. Diabetologia, 49:271–8.
Mata Cases M, Roset Gamisans M, Badia Llach X, et al. 2003. Impacto 
de la disbetes mellitus tipo 2 en la calidad de vida de los pacientes 
tratados en las consultas de atención primaria en España. Atención 
Primaria, 31:493–9.
Mino-Leon D, Figueras A, Amato D, et al. 2005. Treatment of type 2 
diabetes in primary health care: a drug utilization study. Ann Phar-
macother, 39:441–5.
Morisky DE, Green LW, Levine DM. 1986. Concurrent and predictive 
validity of a self-reported measure of medication adherence. Med 
Care, 24:67–74.
Oliva J, Lobo F, Molina B, et al. 2004. Direct health care costs of diabetic 
patients in Spain. Diabetes Care, 27:2616–21.
Olveira G, Soriguer F, Ortega C, et al. 1998. Use of reagent materials 
for self-monitoring in the metropolitan area of Malaga (1994–1996). 
Atención Primaria, 21:75–80.
Roglic G, Unwin N, Bennett PH, et al. 2005. The burden of mortality 
attributable to diabetes: realistic estimates for the year 2000. Diabetes 
Care, 28:2130–35.
Sender Palacios MJ, Vernet Vernet M, Larrosa Sáez P, et al. 2002. Carac-
terísticas sociodemográﬁ  cas y clínicas de una población de pacientes 
con diabetes mellitus. Atención Primaria, 29:474–80.
Spann SJ, Nutting PA, Galliher JM, et al. 2006. Management of type 2 
diabetes in the primary care setting: a practice-based research network 
study. Ann Fam Med, 4:23–31.
Tamayo-Marco B, Faure-Nogueras E, Roche-Asensio MJ, et al. 1997. 
Prevalence of diabetes and impaired glucose tolerance in Aragon, Spain. 
Diabetes Care, 20:534–6.
Tremble JM, Donaldson D. 1999. Is continued weight gain inevitable in 
type 2 diabetes mellitus? J Royal Soc Health, 119:235–9.
Turner R, Cull C, Frighi V, et al. 1999. Glycemic control with diet, 
sulfonylurea, metformin, or insulin in patients with type 2 diabetes 
mellitus: progressive requirement for multiple therapies (UKPDS 49). 
JAMA, 281:2005–12.
[UKPDS] UK Prospective Diabetes Study Group. 1998. Intensive blood-
glucose control with sulphonylureas or insulin compared with con-
ventional treatment and risk of complications in patients with type 2 
diabetes (UKPDS 33). Lancet, 352:837–53.
[WHO] World Health Organization. 2007. Prevalence of diabetes in the 
WHO European region [online]. Accessed March 3, 2007. URL: http://
www.who.int/diabetes/facts/world_ﬁ  gures/en/print.html.
World Health Organization Regional Ofﬁ  ce for Europe. 2007. European 
mortality database. Accessed March 3, 2007. URL: http://data.euro.
who.int/hfamdb/.
Zimmet P, Alberti KG, Shaw J. 2001. Global and societal implications of 
the diabetes epidemic. Nature, 414:782–7.
Zorrilla Torras B, Cantero Real JL, Martínez Cortés M. 1997. Study of 
non-insulin-dependent diabetes mellitus in primary care in the com-
munity of Madrid using network of sentinel physicians. Atención 
Primaria, 20:543–8.